MELMAC: Monitoring Everyday Life Motor Activity in Children

Sponsor
Rob Labruyere (Other)
Overall Status
Terminated
CT.gov ID
NCT02236091
Collaborator
(none)
40
1
46.7
0.9

Study Details

Study Description

Brief Summary

The overall aim of this project is to monitor everyday life activity of children with neurological disorders undergoing rehabilitation using wearable sensors capable of accurate and unobtrusive long-term measurement.

Specific objectives:
  1. To adapt the sensors for the use by children with neurological disorders. The focus lies on the exact positioning and the investigation of the needed amount of IMUs.

  2. To validate the sensor data with collected video recordings and to develop specific algorithms to automatically extract specific movements and to analyze long-term sensor recordings.

  3. To perform a cross-sectional study to assess intensity, task-specificity and duration of upper and lower limb activity during rehabilitation. There, we aim to gain objective information about levels and types of activity during rehabilitation in relation to age, gender and disorder.

  4. To conduct a responsiveness study to assess whether or not the sensor output is able to highlight changes over time during rehabilitation.

Therefore, at time point T=0 (shortly after admission to our center), participants are equipped with 3 inertial measurement units (1 at each wrist and 1 at the sternum). Additionally, a small wearable camera is mounted to the chest. The participants then return to their everyday life for 4 hours (no therapies, measurement period is in the evening). Afterwards, the equipment is removed again. To investigate responsiveness, the same protocol is being repeated 4 weeks later (time point T=1).

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    40 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Cross-Sectional
    Official Title:
    Monitoring Everyday Life Motor Activity in Children
    Actual Study Start Date :
    Oct 1, 2014
    Actual Primary Completion Date :
    Jul 14, 2016
    Actual Study Completion Date :
    Aug 21, 2018

    Arms and Interventions

    Arm Intervention/Treatment
    Inpatients

    Outcome Measures

    Primary Outcome Measures

    1. Counts per minute at time point T=0 [At T=0]

      From the wearable sensors at the wrist, a count/minute statistic is calculated that reflects the amount of activity the child performs during that time.

    2. Counts per minute at time point T=1 [At T=1 (4 weeks after T=0)]

      From the wearable sensors at the wrist, a count/minute statistic is calculated that reflects the amount of activity the child performs during that time.

    Secondary Outcome Measures

    1. Motor assessment: Melbourne 2 at time point T=0 [At T=0]

      The Melbourne Assessment 2: a test of unilateral upper limb function is a validated and reliable tool for evaluating quality of upper limb movement in children with neurological conditions aged 2.5 to 15 years. For ease of use the assessment's full title is simplified to The Melbourne Assessment 2 or MA2. The MA2 is a criterion-referenced test that extends and refines the scale properties of the original Melbourne Assessment. The MA2 measures four elements of upper limb movement quality: movement range, accuracy, dexterity and fluency. It comprises 14 test items of reaching to, grasping, releasing and manipulating simple objects. Each child's test performance is videorecorded for subsequent scoring.

    2. Parent questionnaire: Abilhand-Kids at time point T=0 [At T=0]

      The ABILHAND-Kids is a measure of manual ability for children with upper limb impairments. The scale measures a person's ability to manage daily activities that require the use of the upper limbs, whatever the strategies involved.

    3. Motor assessment: Melbourne 2 at time point T=1 [At T=1 (4 weeks after T=0)]

      The Melbourne Assessment 2: a test of unilateral upper limb function is a validated and reliable tool for evaluating quality of upper limb movement in children with neurological conditions aged 2.5 to 15 years. For ease of use the assessment's full title is simplified to The Melbourne Assessment 2 or MA2. The MA2 is a criterion-referenced test that extends and refines the scale properties of the original Melbourne Assessment. The MA2 measures four elements of upper limb movement quality: movement range, accuracy, dexterity and fluency. It comprises 14 test items of reaching to, grasping, releasing and manipulating simple objects. Each child's test performance is videorecorded for subsequent scoring.

    4. Parent questionnaire: Abilhand-Kids at time point T=1 [At T=1 (4 weeks after T=0)]

      The ABILHAND-Kids is a measure of manual ability for children with upper limb impairments. The scale measures a person's ability to manage daily activities that require the use of the upper limbs, whatever the strategies involved.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    5 Years to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Various neuro-orthopedic diagnoses. Broad inclusion criteria are required to better generalize study results to the patient population of our center.

    • Both walking or in wheelchair, but mobility independent from assisting people

    • Cognitive ability to be able to follow simple verbal instructions.

    • Signed informed consent from legal guardians and also from adolescents aged 15 years or older before study onset.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Rehabilitation Center of the Children's University Hospital Affoltern am Albis Switzerland 8910

    Sponsors and Collaborators

    • Rob Labruyere

    Investigators

    • Principal Investigator: Rob Labruyère, PhD, Children's University Hospital Zurich

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Rob Labruyere, PhD, University Children's Hospital, Zurich
    ClinicalTrials.gov Identifier:
    NCT02236091
    Other Study ID Numbers:
    • MELMAC
    First Posted:
    Sep 10, 2014
    Last Update Posted:
    Oct 17, 2018
    Last Verified:
    Oct 1, 2018
    Keywords provided by Rob Labruyere, PhD, University Children's Hospital, Zurich
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 17, 2018